Design Considerations for Live Biotherapeutic Product Facilities Working with Spore-Forming Bacteria
Live biotherapeutic products (LBPs) create a truly exciting new therapeutic platform with a novel approach to disease treatment and significant potential to improve patient lives. Among the unique challenges that must be addressed in a multiproduct facility manufacturing LBPs is that some species are spore-forming bacteria, which require particularly stringent containment to avoid cross-contamination
DPS Group’s Judy Bodette and Brian Duffy collaborate with Aaron B. Cowley of Arranta Bio to discuss the engineering concepts and considerations for a live biotherapeutic products (LBPs) manufacturing facility in this Pharma’s Almanac article: “Design Considerations for Live Biotherapeutic Product Facilities Working with Spore-Forming Bacteria.”
You may be interested in
